Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed a slight improvement in hair density in men with androgenetic alopecia treated with autologous platelet rich plasma, but only two cases showed cosmetic improvement.

This study found that trichoscopic parameters in male androgenetic alopecia deteriorated progressively with increasing disease severity and were significantly linked to genetic, metabolic, and psychosocial factors.

This review discusses the potential impact of lifestyle factors on the progression of androgenetic alopecia and reports no new clinical findings; the authors emphasize the need for more comprehensive studies.

In this study, the authors highlighted treatments for androgenetic alopecia, noting that combination therapies with drugs like minoxidil and antiandrogens often require at least 6 months for clinical improvement, while also emphasizing the value of patient counseling for informed treatment choices.

In this study conducted at Bangabandhu Sheikh Mujib Medical University, researchers reported that males with androgenetic alopecia had significantly higher levels of serum LH, prolactin, testosterone, DHEA-S, and free androgen index, and lower levels of serum FSH and SHBG compared to those without hair loss.

In this study, researchers identified three novel genetic loci associated with androgenetic alopecia, including one with significant association in females only, which may indicate a role for sex-specific genetic factors in patterned hair loss.

Male hair loss is mainly due to thinner hair, not less hair.

This study found no significant difference in carotid intima-media thickness between individuals with androgenetic alopecia and control subjects.

Hair loss is due to thinner hairs, not less hairs; hair diameter indicates balding progression and treatment effectiveness.

Baldness may indicate higher heart disease risk in men.

This study found that among middle-aged Korean women, those with metabolic syndrome had a higher risk of androgenetic alopecia, while no significant association was observed in men.

This review discusses the latest understanding of androgenetic alopecia, including stem cell niches in hair follicles, and highlights emerging treatments like growth factors and platelet-rich plasma without new clinical findings.

This study found that policemen aged 40-59 years had a twofold higher prevalence of androgenetic alopecia compared to the general population, with obesity and sunlight exposure contributing to the risk.

This study found a significant association between the severity of male pattern baldness and increased levels of depression, loneliness, and internet addiction among male medical students with androgenetic alopecia.

This review discusses the molecular mechanisms of androgens and androgen receptors in skin disorders, particularly androgenetic alopecia, and reports no new clinical results; it highlights potential areas for future treatment development.

In this study, researchers found that while the SNP rs6152 is strongly associated with androgenetic alopecia, the GGN triplet repeat is not, suggesting the causative variant is likely a non-coding one.

Hormones and genetics play key roles in male and female baldness, which can affect mental health and may be linked to other health issues.

Familial factors affect hair loss types in Koreans, with M type in men, L type in women, and paternal factors influencing male hair loss more.

This review examines misconceptions and gaps in the understanding of androgenic alopecia (AGA) etiopathogenesis, offering new perspectives but no new experimental results.

This article discusses the hypothesis that mechanisms driving androgenic alopecia may reduce the risk and proliferation of prostate cancer by increasing prostaglandin D2 levels but presents no new clinical findings.

In this study, researchers observed significant differences in hair follicle microbiome diversity and microbial composition between hair loss and healthy groups, uncovering specific patterns and functional changes associated with female pattern hair loss, which may aid future targeted approaches for androgenetic alopecia.

This study found a very strong positive correlation between sebum levels and the severity of androgenetic alopecia in men.

This study found that men with androgenetic alopecia treated with pumpkin seed oil for 24 weeks experienced a notable 40% increase in hair count compared to a 10% increase with a placebo.

This study found that a new topical botanical lotion significantly increased hair density and improved quality of life in women with androgenetic alopecia over 24 weeks.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This study observed that autologous platelet-rich plasma treatment improved hair count and density in areas with androgenetic alopecia compared to placebo, with differing outcomes based on the PRP collection device used.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This article reviews the use of finasteride for treating male pattern hair loss, highlighting its mechanism of action in reducing DHT and noting its safety profile with some common adverse effects.

This study found that testosterone and 5α-dihydrotestosterone induced apoptosis in dermal papilla cells from nonbalding scalp regions, suggesting a high androgen stimulus can trigger cell death related to androgenetic alopecia.

This study found that moderate to severe androgenetic alopecia is an independent predictor of increased mortality risk from diabetes mellitus and heart disease in both sexes.